| Title |
Propranolol for the treatment of vascular sarcomas
|
|---|---|
| Published in |
Journal of experimental pharmacology, September 2018
|
| DOI | 10.2147/jep.s146211 |
| Pubmed ID | |
| Authors |
Michael J Wagner, Lee D Cranmer, Elizabeth T Loggers, Seth M Pollack |
| Abstract |
Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Spain | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 14% |
| Student > Master | 6 | 14% |
| Student > Ph. D. Student | 5 | 12% |
| Professor > Associate Professor | 5 | 12% |
| Other | 4 | 9% |
| Other | 8 | 19% |
| Unknown | 9 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 21% |
| Veterinary Science and Veterinary Medicine | 7 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Agricultural and Biological Sciences | 3 | 7% |
| Other | 6 | 14% |
| Unknown | 10 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2021.
All research outputs
#6,303,951
of 25,461,852 outputs
Outputs from Journal of experimental pharmacology
#29
of 150 outputs
Outputs of similar age
#101,590
of 345,970 outputs
Outputs of similar age from Journal of experimental pharmacology
#1
of 1 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 150 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,970 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them